Oncology pipeline chief Alessandro Riva joins the exodus at Gilead, heading to helm a biotech spinoff 4 days after O'Day's arrival as CEO
Daniel O’Day’s third work day as the new CEO of Gilead was marked by the departure of one of the company’s top research scientists …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
